Source:http://linkedlifedata.com/resource/pubmed/id/10575269
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
2000-4-11
|
| pubmed:abstractText |
The use of bacillus Calmette-Guérin in the treatment of transitional cell cancer of the bladder has caused concern because of its associated adverse effects. We conducted a randomized prospective, double-blind, multicentre study to determine whether isoniazid prophylaxis could reduce BCG-induced toxicity without compromising its immunotherapeutic effects. Patients (n = 160) with histologically documented urothelial cancer (pTa-T1, pTis, G1-3) were treated with 6 weekly instillations of BCG Connaught strain, 81 mg, administered concomitantly with a 3-day course of isoniazid (300 mg o.d.) or placebo. Side-effects were recorded with each treatment and at follow-up. Of the patients treated with isoniazid, 19% remained free from side-effects, compared with 16% of the placebo group. Local side-effects confined to the bladder were significantly lower among those receiving isoniazid (35% vs. 48%, p < 0.01). Local side-effects together with systemic adverse effects such as fever, nausea or skin rash were experienced by 30% of patients in each arm. There were no differences in tumour recurrence between the two patient groups. Concomitant isoniazid reduces the local, but not the systemic side-effects of topically applied BCG without compromising the antitumour effect on superficial, transitional cell cancer of the bladder during a follow-up period that now exceeds 2 years.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0302-2838
|
| pubmed:author |
pubmed-author:Al KhalifaMM,
pubmed-author:CallaghanPP,
pubmed-author:ColleenSS,
pubmed-author:DuchekMM,
pubmed-author:ElfvingPP,
pubmed-author:ErikssonRR,
pubmed-author:HagbergGG,
pubmed-author:HellstenSS,
pubmed-author:MånssonWW,
pubmed-author:NelsonC ECE,
pubmed-author:NybergGG,
pubmed-author:OlssonRR,
pubmed-author:RademarkCC
|
| pubmed:copyrightInfo |
Copyright 2000 S. Karger AG, Basel
|
| pubmed:issnType |
Print
|
| pubmed:volume |
37 Suppl 1
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
26-30
|
| pubmed:dateRevised |
2009-12-30
|
| pubmed:meshHeading |
pubmed-meshheading:10575269-Administration, Intravesical,
pubmed-meshheading:10575269-Aged,
pubmed-meshheading:10575269-Antitubercular Agents,
pubmed-meshheading:10575269-BCG Vaccine,
pubmed-meshheading:10575269-Carcinoma, Transitional Cell,
pubmed-meshheading:10575269-Carcinoma in Situ,
pubmed-meshheading:10575269-Double-Blind Method,
pubmed-meshheading:10575269-Exanthema,
pubmed-meshheading:10575269-Female,
pubmed-meshheading:10575269-Fever,
pubmed-meshheading:10575269-Humans,
pubmed-meshheading:10575269-Isoniazid,
pubmed-meshheading:10575269-Male,
pubmed-meshheading:10575269-Nausea,
pubmed-meshheading:10575269-Proportional Hazards Models,
pubmed-meshheading:10575269-Prospective Studies,
pubmed-meshheading:10575269-Statistics, Nonparametric,
pubmed-meshheading:10575269-Urinary Bladder Diseases,
pubmed-meshheading:10575269-Urinary Bladder Neoplasms
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
The effect of isoniazid on BCG-induced toxicity in patients with superficial bladder cancer.
|
| pubmed:affiliation |
Department and Sections of Urology, University Hospitals of Lund, Sweden.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|